20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
The AI of the HELIXAFE prevention model based on Cancer Driver Interception includes the integrated analysis of anamnestic data, genomic instability, chronic inflammation, immune system imbalance, and gut dysbiosis. Within the project, the platform will be optimized by developing a customized artificial intelligence system able to analyze multi-layer, longitudinal, cross-sectional, multi-target, and multi-biomarker data. The system will integrate different layers of data coming from multiple tests for every single customer and will extract many different indexes about their health status. The system will be modular, and the output will range from general healthy indexes to those specifically associated with any result of the different analyses accomplished. It will handle and store customers’ data and results, and subsequently indicate personalized chemo-preventive treatments and educative actions to take, thanks to the elaboration of the growing amount of data during the project.
